CN104204807B - 用于胃癌的生物标志物及其应用 - Google Patents

用于胃癌的生物标志物及其应用 Download PDF

Info

Publication number
CN104204807B
CN104204807B CN201380015729.XA CN201380015729A CN104204807B CN 104204807 B CN104204807 B CN 104204807B CN 201380015729 A CN201380015729 A CN 201380015729A CN 104204807 B CN104204807 B CN 104204807B
Authority
CN
China
Prior art keywords
subject
vdbp
expression level
sample
afamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380015729.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104204807A (zh
Inventor
P·霍夫曼
M·佩诺
M·R·W·厄恩斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovation and Commercial Partners Pty Ltd
Original Assignee
Adelaide Research and Innovation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012900233A external-priority patent/AU2012900233A0/en
Application filed by Adelaide Research and Innovation Pty Ltd filed Critical Adelaide Research and Innovation Pty Ltd
Publication of CN104204807A publication Critical patent/CN104204807A/zh
Application granted granted Critical
Publication of CN104204807B publication Critical patent/CN104204807B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CN201380015729.XA 2012-01-20 2013-01-17 用于胃癌的生物标志物及其应用 Expired - Fee Related CN104204807B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012900233 2012-01-20
AU2012900233A AU2012900233A0 (en) 2012-01-20 Biomarkers for gastric cancer and uses thereof
PCT/AU2013/000030 WO2013106886A1 (en) 2012-01-20 2013-01-17 Biomarkers for gastric cancer and uses thereof

Publications (2)

Publication Number Publication Date
CN104204807A CN104204807A (zh) 2014-12-10
CN104204807B true CN104204807B (zh) 2016-11-09

Family

ID=48798425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380015729.XA Expired - Fee Related CN104204807B (zh) 2012-01-20 2013-01-17 用于胃癌的生物标志物及其应用

Country Status (7)

Country Link
US (3) US20150010914A1 (enExample)
EP (1) EP2805167B1 (enExample)
JP (1) JP6198752B2 (enExample)
CN (1) CN104204807B (enExample)
AU (1) AU2013210776B2 (enExample)
NZ (1) NZ629074A (enExample)
WO (1) WO2013106886A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2511525A (en) * 2013-03-05 2014-09-10 Randox Teoranta Methods and Compositions for the Diagnosis of Alzheimer's Disease
CA3210007A1 (en) * 2013-03-15 2014-09-18 Sera Prognostics, Inc Biomarkers and methods for predicting preeclampsia
KR101452730B1 (ko) * 2014-02-19 2014-10-23 한국과학기술원 신규한 위암 진단방법
KR101484969B1 (ko) * 2014-03-26 2015-01-22 충남대학교산학협력단 Ｎ-당쇄화된 당펩타이드를 이용한 암 진단방법
CN105572354B (zh) * 2014-10-17 2018-02-02 广州瑞博奥生物科技有限公司 一种检测早期胃癌的抗体芯片试剂盒
KR101803287B1 (ko) 2015-06-15 2017-12-01 한국과학기술연구원 키누레닌 대사 비율 변화를 이용한 위암 진단용 키트
JP2019509485A (ja) * 2016-03-09 2019-04-04 バイオメリカ・インコーポレイテッドＢｉｏｍｅｒｉｃａ， Ｉｎｃ． 機能性消化不良感受性試験の組成物、デバイスおよび方法
US11636924B2 (en) 2016-09-30 2023-04-25 Molecular Devices, Llc Computer device for detecting an optimal candidate compound and methods thereof
CN106519007B (zh) * 2016-12-12 2019-07-02 王家祥 一种单链多肽及其在制备用于预防和治疗胃癌的药物中的应用
CN106872704A (zh) * 2017-03-17 2017-06-20 中国科学院上海高等研究院 八种蛋白质用作鉴定浆膜层浸润深度胃癌的分子标记的应用
WO2019217375A1 (en) * 2018-05-07 2019-11-14 Children's Hospital Medical Center Vitamin d binding protein in the clinical management of hematopoietic stem cell transplantation
WO2020138561A1 (ko) * 2018-12-28 2020-07-02 경상대학교병원 뇌수막염 진단을 위한 정보제공방법
CN110297094A (zh) * 2019-07-01 2019-10-01 北京大学第一医院 检测afamin浓度的试剂盒、制备方法及测定afamin浓度的方法
CA3202252A1 (en) * 2020-12-21 2022-06-30 Eliette Camille TOUATI Biomarkers signature(s) for the prevention and early detection of gastric cancer
CN113466465A (zh) * 2021-01-20 2021-10-01 浙江大学滨海产业技术研究院 一种基于蛋白质组学的唾液检测方法
CN113174445B (zh) * 2021-04-21 2023-03-21 广西壮族自治区农业科学院 分析慈姑不同组织的内参基因及其筛选方法和应用
CN118671346B (zh) * 2024-08-22 2024-11-15 浙江省肿瘤医院 用于胃癌诊断的代谢标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100183A1 (en) * 2006-02-28 2007-09-07 Bioinfra Inc. Protein markers for diagnosing stomach cancer and the diagnostic kit using them
JP2008263840A (ja) * 2007-04-19 2008-11-06 Toray Ind Inc 胃ガンの診断又は検出のための組成物及び方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
ATE242485T1 (de) 1993-05-28 2003-06-15 Baylor College Medicine Verfahren und massenspektrometer zur desorption und ionisierung von analyten
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
AU4025300A (en) 1999-03-24 2000-10-09 Packard Bioscience Company Continuous porous matrix arrays
CA2469403C (en) 2001-12-05 2015-06-02 Jonathan Mark Boutell Protein arrays for allelic variants and uses thereof
JP2005516114A (ja) 2002-01-25 2005-06-02 サイファージェン バイオシステムズ， インコーポレイテッド 被分析物の脱離／イオン化に有用なエネルギー吸収部分を有するモノマーおよびポリマー
EP2012127A3 (en) 2007-07-03 2009-03-11 Koninklijke Philips Electronics N.V. Diagnostic markers for detecting prostate cancer
CN102844661B (zh) * 2010-02-11 2014-06-25 香港理工大学 胃癌的生物标志物及其应用
AU2011229130A1 (en) 2010-03-17 2012-11-01 Adelaide Research & Innovation Pty Ltd A sensor and a method for characterising a dielectric material

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100183A1 (en) * 2006-02-28 2007-09-07 Bioinfra Inc. Protein markers for diagnosing stomach cancer and the diagnostic kit using them
JP2008263840A (ja) * 2007-04-19 2008-11-06 Toray Ind Inc 胃ガンの診断又は検出のための組成物及び方法

Also Published As

Publication number Publication date
JP2015505370A (ja) 2015-02-19
JP6198752B2 (ja) 2017-09-20
NZ629074A (en) 2016-09-30
EP2805167A4 (en) 2015-12-09
US20160370373A1 (en) 2016-12-22
WO2013106886A1 (en) 2013-07-25
CN104204807A (zh) 2014-12-10
US20190285637A1 (en) 2019-09-19
AU2013210776A1 (en) 2014-09-11
US10345309B2 (en) 2019-07-09
US20150010914A1 (en) 2015-01-08
EP2805167A1 (en) 2014-11-26
HK1206414A1 (en) 2016-01-08
EP2805167B1 (en) 2020-04-22
AU2013210776B2 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
CN104204807B (zh) 用于胃癌的生物标志物及其应用
US20250123283A1 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
Sepiashvili et al. Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy
JP6786499B2 (ja) 膵癌のバイオマーカー
WO2021076036A1 (en) Apparatuses and methods for detection of pancreatic cancer
EP3066474B1 (en) Bladder carcinoma biomarkers
US20200249235A1 (en) Methods for diagnosing pancreatic cancer
US20140274794A1 (en) Methods and Compositions for Diagnosis of Ovarian Cancer
JP2008527351A (ja) 前立腺癌のバイオマーカーとしてのアポリポタンパク質ａ−ｉｉアイソフォーム
CN111065925B (zh) Agrin在诊断子宫内膜癌中的应用
KR101334123B1 (ko) 소세포폐암 진단용 조성물 및 소세포폐암 진단키트
HK1206414B (en) Biomarkers for gastric cancer and uses thereof
CA3214819A1 (en) Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
HK1245295A1 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
HK1245295B (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161109